243 related articles for article (PubMed ID: 36906141)
1. The role of VEGF in cancer-induced angiogenesis and research progress of drugs targeting VEGF.
Ghalehbandi S; Yuzugulen J; Pranjol MZI; Pourgholami MH
Eur J Pharmacol; 2023 Jun; 949():175586. PubMed ID: 36906141
[TBL] [Abstract][Full Text] [Related]
2. Reassessing vascular endothelial growth factor (VEGF) in anti-angiogenic cancer therapy.
Elebiyo TC; Rotimi D; Evbuomwan IO; Maimako RF; Iyobhebhe M; Ojo OA; Oluba OM; Adeyemi OS
Cancer Treat Res Commun; 2022; 32():100620. PubMed ID: 35964475
[TBL] [Abstract][Full Text] [Related]
3. Vascular endothelial cell growth factor (VEGF), an emerging target for cancer chemotherapy.
Shinkaruk S; Bayle M; Laïn G; Déléris G
Curr Med Chem Anticancer Agents; 2003 Mar; 3(2):95-117. PubMed ID: 12678905
[TBL] [Abstract][Full Text] [Related]
4. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
Zhao Y; Adjei AA
Oncologist; 2015 Jun; 20(6):660-73. PubMed ID: 26001391
[TBL] [Abstract][Full Text] [Related]
5. Loss of apelin blocks the emergence of sprouting angiogenesis in experimental tumors.
Azad AK; Campbell KR; Zhabyeyev P; Oudit GY; Moore RB; Murray AG
FASEB J; 2022 Oct; 36(10):e22560. PubMed ID: 36165236
[TBL] [Abstract][Full Text] [Related]
6. Vascular endothelial growth factor and vascular endothelial growth factor receptor inhibitors as anti-angiogenic agents in cancer therapy.
Veeravagu A; Hsu AR; Cai W; Hou LC; Tse VC; Chen X
Recent Pat Anticancer Drug Discov; 2007 Jan; 2(1):59-71. PubMed ID: 18221053
[TBL] [Abstract][Full Text] [Related]
7. Anti-Angiogenic Therapy: Current Challenges and Future Perspectives.
Lopes-Coelho F; Martins F; Pereira SA; Serpa J
Int J Mol Sci; 2021 Apr; 22(7):. PubMed ID: 33916438
[TBL] [Abstract][Full Text] [Related]
8. Direct and Indirect Modulation of T Cells by VEGF-A Counteracted by Anti-Angiogenic Treatment.
Bourhis M; Palle J; Galy-Fauroux I; Terme M
Front Immunol; 2021; 12():616837. PubMed ID: 33854498
[TBL] [Abstract][Full Text] [Related]
9. Novel Drugs with High Efficacy against Tumor Angiogenesis.
Qi S; Deng S; Lian Z; Yu K
Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35805939
[TBL] [Abstract][Full Text] [Related]
10. Brain angiogenesis in developmental and pathological processes: therapeutic aspects of vascular endothelial growth factor.
Shibuya M
FEBS J; 2009 Sep; 276(17):4636-43. PubMed ID: 19664071
[TBL] [Abstract][Full Text] [Related]
11. Targeting tumor micro-environment for design and development of novel anti-angiogenic agents arresting tumor growth.
Gacche RN; Meshram RJ
Prog Biophys Mol Biol; 2013 Nov; 113(2):333-54. PubMed ID: 24139944
[TBL] [Abstract][Full Text] [Related]
12. Expression of vascular endothelial growth factor (VEGF) and VEGF receptors in tumor angiogenesis and malignancies.
Pradeep CR; Sunila ES; Kuttan G
Integr Cancer Ther; 2005 Dec; 4(4):315-21. PubMed ID: 16282508
[TBL] [Abstract][Full Text] [Related]
13. Dual blockade of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (FGF-2) exhibits potent anti-angiogenic effects.
Li D; Xie K; Zhang L; Yao X; Li H; Xu Q; Wang X; Jiang J; Fang J
Cancer Lett; 2016 Jul; 377(2):164-73. PubMed ID: 27130666
[TBL] [Abstract][Full Text] [Related]
14. Angiopoietin inhibitors: A review on targeting tumor angiogenesis.
Parmar D; Apte M
Eur J Pharmacol; 2021 May; 899():174021. PubMed ID: 33741382
[TBL] [Abstract][Full Text] [Related]
15. Angiogenesis and hypertension: the dual role of anti-hypertensive and anti-angiogenic therapies.
Ferroni P; Della-Morte D; Palmirotta R; Rundek T; Guadagni F; Roselli M
Curr Vasc Pharmacol; 2012 Jul; 10(4):479-93. PubMed ID: 22272903
[TBL] [Abstract][Full Text] [Related]
16. Trends and Challenges in Tumor Anti-Angiogenic Therapies.
Jászai J; Schmidt MHH
Cells; 2019 Sep; 8(9):. PubMed ID: 31540455
[TBL] [Abstract][Full Text] [Related]
17. Tumor angiogenesis and anti-angiogenic therapies.
Shahneh FZ; Baradaran B; Zamani F; Aghebati-Maleki L
Hum Antibodies; 2013; 22(1-2):15-9. PubMed ID: 24284305
[TBL] [Abstract][Full Text] [Related]
18. Clinical experience with angiogenesis signaling inhibitors: focus on vascular endothelial growth factor (VEGF) blockers.
Rosen LS
Cancer Control; 2002; 9(2 Suppl):36-44. PubMed ID: 11965229
[TBL] [Abstract][Full Text] [Related]
19. Exploring the Immunological Mechanisms Underlying the Anti-vascular Endothelial Growth Factor Activity in Tumors.
de Aguiar RB; de Moraes JZ
Front Immunol; 2019; 10():1023. PubMed ID: 31156623
[TBL] [Abstract][Full Text] [Related]
20. Angiogenesis--a new target for future therapy.
Pandya NM; Dhalla NS; Santani DD
Vascul Pharmacol; 2006 May; 44(5):265-74. PubMed ID: 16545987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
